The physicians looked at several clinical trials to create evidence-based guidelines. They found a loading phase of three monthly injections of ranibizumab 0.5 mg, an anti-angiogenic that has been approved to treat ARMD, provided the best improvement in visual acuity. They also found starting treatment within two weeks of diagnosis provided the best outcome, and waiting more than one month to start treatment led to further vision loss.
Related Articles on Ophthalmology:
BIOLASE Laser Technology Issued Patent to Treat Eye Conditions
Vision Treatment Company AcuFocus Raises $65M in Funding
Cataract Surgery Gains Popularity as Surgical Option for Glaucoma
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
